Chen Schor - Net Worth and Insider Trading

Chen Schor Net Worth

The estimated net worth of Chen Schor is at least $1 Million dollars as of 2024-04-27. Chen Schor is the President and CEO of resTORbio Inc and owns about 270,337 shares of resTORbio Inc (TORC) stock worth over $616,368. Chen Schor is also the President & CEO of Adicet Bio Inc and owns about 250,654 shares of Adicet Bio Inc (ACET) stock worth over $421,099. Details can be seen in Chen Schor's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Chen Schor has not made any transactions after 2023-10-02 and currently still holds the listed stock(s).

Transaction Summary of Chen Schor

To

Chen Schor Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Chen Schor owns 4 companies in total, including Brainstorm Cell Therapeutics Inc (BCLI) , Madrigal Pharmaceuticals Inc (MDGL) , and Karyopharm Therapeutics Inc (KPTI) among others .

Click here to see the complete history of Chen Schor’s form 4 insider trades.

Insider Ownership Summary of Chen Schor

Ticker Comapny Transaction Date Type of Owner
BCLI Brainstorm Cell Therapeutics Inc 2011-08-22 director
MDGL Madrigal Pharmaceuticals Inc 2015-09-16 director & President and CEO
KPTI Karyopharm Therapeutics Inc 2020-11-25 director
ACET Adicet Bio Inc 2023-10-02 director & See Remarks

Chen Schor Latest Holdings Summary

Chen Schor currently owns a total of 2 stocks. Among these stocks, Chen Schor owns 270,337 shares of resTORbio Inc (TORC) as of April 16, 2018, with a value of $616,368 and a weighting of 59.41%. Chen Schor also owns 250,654 shares of Adicet Bio Inc (ACET) as of October 2, 2023, with a value of $421,099 and a weighting of 40.59%.

Latest Holdings of Chen Schor

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
TORC resTORbio Inc 2018-04-16 270,337 2.28 616,368
ACET Adicet Bio Inc 2023-10-02 250,654 1.68 421,099

Holding Weightings of Chen Schor


Chen Schor Form 4 Trading Tracker

According to the SEC Form 4 filings, Chen Schor has made a total of 0 transactions in resTORbio Inc (TORC) over the past 5 years. The most-recent trade in resTORbio Inc is the acquisition of 286 shares on April 16, 2018, which cost Chen Schor around $17,900.

According to the SEC Form 4 filings, Chen Schor has made a total of 14 transactions in Adicet Bio Inc (ACET) over the past 5 years, including 1 buys and 13 sells. The most-recent trade in Adicet Bio Inc is the acquisition of 11,000 shares on October 2, 2023, which cost Chen Schor around $15,180.

Insider Trading History of Chen Schor

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Chen Schor Trading Performance

GuruFocus tracks the stock performance after each of Chen Schor's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Chen Schor is 11.25%. GuruFocus also compares Chen Schor's trading performance to market benchmark return within the same time period. The performance of stocks bought by Chen Schor within 3 months outperforms 1 times out of 4 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Chen Schor's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Chen Schor

Average Return

-19.63%

Average return per transaction

Outperforming Transactions

0%

0 out of 3 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 19.18 11.25 40.99 -19.63 -65.04
Relative Return to S&P 500(%) 17.16 4.93 32.38 -28.5 -67.53

Chen Schor Ownership Network

Ownership Network List of Chen Schor

No Data

Ownership Network Relation of Chen Schor


Chen Schor Owned Company Details

What does Brainstorm Cell Therapeutics Inc do?

Who are the key executives at Brainstorm Cell Therapeutics Inc?

Chen Schor is the director of Brainstorm Cell Therapeutics Inc. Other key executives at Brainstorm Cell Therapeutics Inc include EVP & Head Global Clin Research Stacy Lindborg , Chief Medical Officer Kirk Taylor , and See Remarks Alla Patlis .

Brainstorm Cell Therapeutics Inc (BCLI) Insider Trades Summary

Over the past 18 months, Chen Schor made no insider transaction in Brainstorm Cell Therapeutics Inc (BCLI). Other recent insider transactions involving Brainstorm Cell Therapeutics Inc (BCLI) include a net purchase of 11,500 shares made by Stacy Lindborg ,

In summary, during the past 3 months, insiders sold 0 shares of Brainstorm Cell Therapeutics Inc (BCLI) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Brainstorm Cell Therapeutics Inc (BCLI) were sold and 11,500 shares were bought by its insiders, resulting in a net purchase of 11,500 shares.

Brainstorm Cell Therapeutics Inc (BCLI)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Brainstorm Cell Therapeutics Inc Insider Transactions

No Available Data

Chen Schor Mailing Address

Above is the net worth, insider trading, and ownership report for Chen Schor. You might contact Chen Schor via mailing address: Predix Pharmaceuticals Holdings, Inc., 4 Maguire Road, Lexington Ma 02421.

Discussions on Chen Schor

No discussions yet.